Chronic myelogenous leukemia is characterized by the Philadelphia chromosome, which at the molecular level results from the fusion of the bcr gene on chromosome 22 and the ablgene on chromosome 9. The bcr-ablfusion gene encodes a novel tyrosine kinase with transforming activity. In this study, we have synthesized a multi-unit ribozyme that targets bcr-ab/ mRNA. In vitro ribozyme cleavage reactions show increased cleavage efficiency of this multi-unit ribozyme compared with single or double ribozymes. The multiunit ribozyme was then transfected into murine myeloblasts HRONIC myelogenous leukemia (CML) accounts for 20% of all cases of leukemia and carries a death rate of 1.5 per 100,000 population.' In 1960, Nowell and Hungerford discovered that the Philadelphia chromosome (Ph') was consistently associated with CML.2-4 Molecular studies have shown that during the formation of the Ph chromosome, a portion of the c-ab1 gene is translocated from chromosome 9q34 to chromosome 22qll resulting in the formation of a chimeric gene consisting of sequences derived from the bcr and ubl
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This translocation is detectable in over 95% of patients with CML. The transcript of this gene either includes (b3a2) or excludes (b2a2) exon 3 of the bcr gene. The fusion gene, named bcr-abl, transcribes a chimeric mRNA of 8.5 kb that is translated into a p210 fusion protein with altered tyrosine kinase activity.'.' The p210h"""'" protein has been shown to transform myeloid precursor cells in vitro,' and infection of primary murine bone marrow (BM) stem cells with a retrovirus encoding the bcr-abl protein predictably produced a disorder in mice similar to human
In the past decade, the use of antisense nucleic acid sequences to block the translation of mRNA has been developed as a strategy to inhibit viral and malignant diseases. Recently, it has been shown that specific RNA sequences, termed ribozymes, have the ability to cleave other RNA molecules in a catalytic manner. Several different catalytic sequences have been described that share a common need for divalent cations and result in the nonhydrolytic transesterification of specific RNA target regions." These catalytic sequences have been adapted to create targeted antisense molecules that bind to and cleave target RNA molecules." I' 0 l995 b y The American Society of Hematology.
The "hammerhead" ribozyme has been developed into a targeted ribozyme, employing a catalytic "hammerhead" domain and flanking oligonucleotides that specifically bind to target sequences." Cleavage occurs 3' to a GUX triplet where X can be C , U, or A . "~" Any GUX sequence can be targeted by the appropriate design of the flanking oligonucleotide sequence. Recently, a few studies have used antisense molecules or ribozymes to specifically target the bcr-ab1 gene.'x-20 Examination of the b3a2 bcr-ab1 junction sequences shows the presence of three closely spaced GUX sequences near the breakpoint. In this communication, we have designed a multi-unit ribozyme that targets these three cleavage sites and have compared its efficacy with singleunit ribozymes that target these GUX sequences individually. Our results show that multi-unit ribozymes have a greater efficacy of cleavage compared with that of singleunit ribozymes. To test the feasibility of using multi-unit ribozymes as a purging strategy for autologous BM transplantation (BMT) in CML, we studied the in vitro activity of this ribozyme and the effects of ribozyme transfection on bcr-ab1 mRNA levels in bcr-abl-transformed 32D cells. Our results show that folic acid-polylysine is an effective carrier molecule for ribozymes and that bcr-abl-transformed 32D cells transfected with an anti-bcr-ab1 triple-unit ribozyme via the folic acid-polylysine method reduced the level of bcr-ab1 mRNA 3 logs.
MATERIALS AND METHODS
Svnthesis of the multi-unit ribozyme. cDNAs encoding singleunit ribozymes were synthesized as complimentary oligonucleotide molecules. Double-and triple-unit ribozyme expression vectors were produced by ligation of single-unit ribozyme cDNAs. Single-, double., and triple-unit ribozyme cDNAs were cloned into pGEM3z vector (Promega, Madison, WI). Ribozyme RNA was transcribed using SP6 RNA polymerase in vitro as per manufacturer's protocol (Promega). Cleavage-inactive control ribozyrnes, with a G substituted for the A in the conserved GAG sequence in the catalytic unit eliminating catalytic function," were similarly cloned and transcribed. Sense ribozymes were synthesized by transcription from the opposite strand in pGEM3z vector using T7 RNA polymerase.
Target mRNA synthesis. cDNA encoding the bcr-abl breakpoint region, a portion of the bcr gene, and a portion of the ab1 gene were cloned into pGEM3, pGEM5, pGEM3z vectors (Promega), respectively. RNA was transcribed using "P-UTP and T7, T3, and SP6 RNA polymerases (Promega), respectively, according to the manufacturer's protocol.
Ribozyme cleavage reactions. Substrate and ribozyme reactions were performed using RNA concentrations of 100 nmol/L in IO-$- volumes. All RNA was suspended in 50 mmoVL Tris-HC1, pH 7.5, containing l mmoVL EDTA and was heated to 95°C for 5 minutes and immediately chilled on ice. Reactions were initiated by adding 1 pL of 200 mmol/L MgC12 and stopped after 2 hours by adding 2 pL of stop solution containing 95% formamide, 20 mmoVL EDTA, and 2% bromophenol blue. Cleavage products were analyzed by electrophoresis on a 6% denaturing gel followed by autoradiography and quantitative densitometry (Fujix, Tokyo, Japan). The kinetics of ribozyme cleavage were determined in identical experiments by removing 1 pL of the reaction mixture at specified times and adding 1 pL of stop solution. Cleavage products were analyzed as above. 320 cell transformation. 32D cells, a murine BM myeloblast cell line, was maintained in Iscove's modified Dulbecco's media (IMDM) with 10% fetal bovine serum (FBS), and 10% WEHI-322 supernatant as a source of murine interleukin-3 (IL-3). Retroviral expression vectors expressing the bcr-abl gene along with neomycin resistance genez3 were introduced into 32D cells by electroporation. A total of 10 pg of linearized DNA was electroporated into 32D cells using 300 V and 960 microfarads using the BioRad Gene Pulser (BioRad, Hercules, CA) according to the manufacturer's protocol. Transformed cells were selected by growth in L-3-deficient medium containing neomycin. The presence of the ~2 1 0 " "~' tyrosine kinase was confirmed by Northern blotting and immunoprecipitation analysis (data not shown).
Ribozyme transfection of bcr-abl-transformed 320 cells. Ribozymes were transcribed with SP6 RNA polymerase as described above. bcr-abl-transformed 32D cells were maintained in IMDM with 10% FBS. All cells were washed twice in purified buffered saline before transfection. In liposome transfection experiments, bcrabl-transformed 32D cells were suspended in serum-free IMDM. Liposomes containing ribozyme RNA were prepared in 100 pL of RNase-free water as per the manufacturer's instructions. Briefly, RNA and lipofectin (GIBCO, Gaithersburg, MD) were each suspended in 50 pL of water and gently mixed for 15 minutes. The transfection mix was added to 4 mL of medium containing 1 X lo6 cells.
When the folic acid-polylysine method was used for transfection, the protocols described by Reddy et alB were used. The folate conjugation number was determined by measuring the optical density at 363 nm of the conjugate solution, and the conjugation number was 3 to 4 folate molecules per polylysine molecule. Briefly, folic acidpolylysine and RNA mixtures were prepared in 150 mmom NaCl, 20 mmoVL HEPES, pH 7.3, using RNAse-free water and were gently mixed for 15 minutes. The transfection mix was added to 4 mL of serum-free, folate-free Dulbecco's modified Eagle's medium containing 1 X lo6 cells. Before transfection, bcr-dl-transformed 32D cells were grown in this medium with 10% FBS for 3 days. FBS and IL-3, to a final concentration of IO%, were added 3 hours after the completion of the transfection protocol.
BCR-ABL mRNA analysis. A total of 1 X lo6 32D cells were added to increasing numbers of bcr-abl-transformed 32D cells and transfected with ribozyme molecules using either liposomes or folic acid-polylysine vectors. Inactive ribozyme or transfection medium containing no ribozyme was used as negative control. Plasmid pGEM 5 described above, containing the bcr-ab1 breakpoint, was used to transcribe RNA used as the positive control for the reverse transcription-polymerase chain reaction (RT-PCR) analysis. The number of bcr-abl-transformed 32D cells added varied from 1 to 1 X 104 cells per 1 million normal 32D cells. Cells were transfected at time zero, and 3 hours after transfection, the medium was supplemented with FBS and L -3 as described above. Total cellular RNA was isolated by lysing cells in Ultraspec solution (Biotecx, Houston, TX) according to the manufacturer's protocol. RT-PCR was performed as previously de~cribed.2~ After RT with an oligo dT primer, PCR amplification was performed as follows: precycle at 95°C for 2 minutes and 30 cycles at 94°C for 30 seconds, 54°C for 30 seconds, and 72°C for 1 minute. After PCR amplification, the samples were heated to 72°C for 10 minutes to allow completion of extension. The primer sequences were 5'-GGAGCTGCAGATGCTGACCA C and 5'-TCAGACCCTGAGGCTCAAAG TC. The @-actin gene transcript was also amplified as an internal control. Twenty microliters of the PCR product was analyzed by electrophoresis on a 1.5% agarose gel and photographed. Southern blotting was performed as described elsewhere26 using a "P-kinased oligonucleotide probe spanning the bcr-abl junction. The probe sequence was 5'-GCTGAAGGGClTITGAACTC TGCTT'A.
RESULTS

Ribozyme design, synthesis, and packaging. To develop ribozyme-based reactions as a potential therapy for human
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From leukemias, we have designed hammerhead motifs that can cleave specifically bcr-ab1 mRNA, thereby preventing the synthesis of the transforming fusion protein. Single-, double-, and triple-unit ribozymes were designed and constructed targeting GUX sequences near the bcr-ab1 fusion site (Fig l ) . Single-unit ribozymes were synthesized as cDNA oligomers, whereas double-and triple-unit ribozyme expression vectors were produced by ligation of single-unit ribozyme cDNAs. Nonfunctional ribozymes (antisense controls), with a G substituted for the A in the conserved GAG sequence (marked with an asterisk in Fig 1) in the catalytic unit eliminating catalytic function," were similarly cloned and transcribed. Sense ribozymes were synthesized by transcription from the opposite strand in pGEM3z vector using T7 RNA polymerase.
In vitro ribozyme cleavage reactions.
To test the efficiency of single-, double-, and triple-unit ribozymes, we performed in vitro cleavage reactions. Four single-unit ribozymes, two double-unit ribozymes, and one triple-unit ribozyme, whose structures are shown in Fig I , were used in these studies. A constant amount of "P-labeled substrate bcr-abl RNA was incubated with equal molar amounts of LEOPOLD ET AL various ribozymes for 2 hours, and the cleavage products were analyzed on a denaturing polyacrylamide gel as described in Materials and Methods. As shown in Fig 2A, single-, double-, and triple-unit ribozymes specifically cleave bcr-ab1 mRNA. After 2 hours, single ribozymes cleaved target bcr-ab1 mRNA into 2 fragments with variable efficiency. Ribozymes A, B, C, and D cleaved 45%, 79%, 5%, and 7% of target mRNA, respectively. Comparison among these ribozymes shows that ribozymes targeting the same site but with shorter annealing arms are more efficient (A v C) and GUC cleavage sites (ribozyme B) appear to be more efficiently cleaved. The variability in cleavage of substrate RNA by ribozymes B, C, and D is not surprising and reflects the expected cleavage efficiency at different GUX cleavage sites.'' Double-unit ribozymes E and F cleaved 72% and 13% of target mRNA, respectively. There was no significant improvement in cleavage over the best single ribozyme of the pair. However, ribozyme F, the triple-unit ribozyme, cleaved 95% of target mRNA in 2 hours. Figure 2B shows the cleavage obtained when all 3 single unit ribozymes are added together in one reaction. This resulted in little additional cleavage compared with that of the best single ribo- zyme (ribozyme B). There was no cleavage of bcr-ab1 mRNA using sense-oriented ribozymes and cleavage-inactive antisense ribozymes (data not shown).
The kinetics of in vitro cleavage are shown in Fig 3. As described in Materials and Methods, equal molar amounts of "P-labeled bcr-ab1 substrate was incubated with singleor triple-unit ribozymes for various times, and aliquots were analyzed over time for percentage of cleavage. Ribozyme C was used as the single-unit ribozyme for comparison because its sequence was contained within the triple-unit ribozyme and targets the bcr-ab1 junction. Ribozymes B and D target normal bcr and ab1 sequences and would not be specific for bcr-ab/ sequences. These ribozymes would have little clinical utility. By 30 minutes, cleavage of target mRNA by the triple-unit ribozyme is nearly complete, whereas the single ribozyme has had little effect on the same target mRNA.
To test the specificity of the triple-unit ribozyme, c-ab/ and c-bcr mRNA containing the breakpoint region was transcribed with '*P-CTP and used as a target for single-and triple-unit ribozymes in similar 2-hour cleavage reactions. Figure 4 shows specific cleavage products from these reactions. In Fig 4A, ribozyme D cleaved 3% and ribozyme G cleaved 87% of c-ab1 mRNA. In Fig 4B, ribozyme B cleaved 83% and ribozyme G cleaved 45% of target bcr mRNA. Thus, the more efficient triple-unit bcr-ab1 ribozyme does cleave c-ab/ and bcr mRNA, although less efficiently as compared with bcr-ab1 sequences.
Ribozyme transfection of transformed 32D cells. Having shown that the triple-unit ribozyme efficiently cleaved bcrab1 mRNA, we next compared two transfection techniques to standardize a transfection protocol for use in subsequent experiments. For comparison, we used either lipofectin2' or folic acid-polylysine? because these two reagents have been reported to yield high levels of transfection. The transfection protocols were standardized by varying both the concentration of transfection vehicle and RNA over 4 logs and the incubation time. After 3 hours of ribozyme exposure, total cellular RNA was isolated from bcr-ab/-transformed 32D cells and was analyzed by electrophoresis on a 6% sequencing gel followed by autoradiography and quantitative densitometry. Figure 5A shows the improvement in "P-labeled ribozyme uptake in 32D cells that results by incorporating the ribozyme in a liposome. Naked multi-unit ribozymes are poorly taken up by cells (Fig 5A, lane l) , whereas liposomes augmented delivery 100-fold (Fig 5A, lane 2) . In addition to isolating total cellular RNA and comparing ribozyme delivery, the supernatant from these transfection experiments was monitored for ribozyme stability. Naked ribozymes were degraded over several hours, whereas ribozymes packaged in liposomes remained stable in serum-free medium for 24 hours (data not shown). Analysis of cellular RNA after 3 hours of ribozyme exposure insured that uptake comparisons were made during the period of time in which ribozymes were present under all transfection conditions.
Figure 5B Transfection standardization. To further optimize the transfection conditions, a series of experiments were performed to determine the dose-response relationship between ribozyme and transfection vehicle concentration in 32D cells. First, 1 X IO6 cells were transfected with 1 pg of 32P-labeled triple-unit ribozyme via increasing concentrations of liposomes or folic acid-polylysine. Next, based on these dose-response curves, the quantity of transfection vehicle was held constant and the quantity of ribozyme was varied. Then, using optimum ratios of ribozyme and transfection vehicle, the time course for ribozyme uptake and survival was determined. Figure 6 graphically shows the results from these experiments in 32D cells. Although both transfection techniques augmented ribozyme uptake, folate receptor-mediated transfection improved uptake up to IO-fold. Furthermore, multi-unit ribozyme RNA remained at significant intracellular levels in 32D cells after 24 hours. This occurred despite the addition of FBS to the culture medium after 3 hours, which quickly degraded ribozyme RNA in the medium (data not shown). In subsequent transfection experiments either, 5 pg of lipofectin was diluted in 50 pL of water and mixed with 1 pg of RNA suspended in 50 pL of water or 1 pL of folic acid-polylysine was diluted in 50 pL HEPES-buffered saline and mixed with 1 pg of RNA suspended in 50 pL HEPES-buffered saline was used.
Serial transfections. To test the availability of the folate receptor for serial transfections, 32D cells were serially transfected with unlabeled and "P-labeled ribozymes over a 48-hour period. Three identical folic acid-polylysine transfection experiments were performed at time zero with either -"P-labeled (one sample) or unlabeled ribozymes (two samples). After 3 hours, the cells transfected with labeled ribozymes were lysed and RNA was isolated, whereas cells transfected with unlabeled ribozymes were supplemented with FBS and IL-3 as described above. After 24 hours, one of the two remaining samples was then washed in purified buffered saline and transfected with "P-labeled ribozyme. After 3 additional hours, these cells were washed and lysed, and RNA was isolated. A second transfection with unlabeled ribozymes was performed on the remaining cells (second dose), and these cells were supplemented as described. After 48 hours, these cells were transfected with labeled ribozymes (third dose), and, after 3 hours, RNA was isolated as described above. The RNA samples were analyzed by electrophoresis on a 6% denaturing polyacrylamide gel electrophoresis followed by autoradiography and quantitative densitometry. Figure 7 shows the autoradiogram that demonstrates that serial folic acid-polylysine transfection results in a decrease in ribozyme uptake. Compared with the quantity of "P-labeled ribozyme recovered from cells at 3 hours, 50% was recovered after the second transfection, and 60% was recovered after the third transfection. These experiments show that less ribozyme is delivered during sequential folate receptor-targeted transfections in 32D cells, probably because of receptor occupancy or downregulation of receptor density on the cell surface.
RNA analysis. To test the ability of the multi-unit ribozyme to cleave bcr-abl mRNA in cells, untransformed 32D cells were added to various numbers of bcr-abl-transformed 32D cells and were transfected 1 or 3 times over 24 or 48 hours respectively, with triple-unit ribozyme via liposomes or folic acid-polylysine vectors. Total cellular RNA was isolated after 24 and 48 hours and was reverse-transcribed into cDNA. The cDNA was amplified by PCR using primers that amplify the bcr-ab1 breakpoint. Purified cellular RNA was DNA-free, and there was no amplification of DNA in the absence of RT. suggesting only reverse-transcribed RNA is being amplified (data not shown). Figure 8 shows the results of a Southern blot performed on the PCR products using an oligonucleotide probe that spans the bcr-ab1 breakpoint. Control cells transfected with folic acid-polylysine vectors alone show that this technique has a sensitivity for detecting 1 transformed cell in 1 X 10' normal cells. A single transfection of the triple-unit ribozyme via folic acid-polylysine vectors into bcr-abl-transformed 32D cells resulted in a 3-log 
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decrease in detectable bcr-ah1 mRNA signal 24 hours after transfection. There was no improvement in reducing the bcrah1 mRNA with multiple transfections over 48 hours compared with single transfections (data not shown). A I-log reduction in bcr-ah1 RNA content was observed by transfection of ribozymes via liposomes, despite multiple treatments over 48 hours (24 hour data shown in Fig 8) . Cleavageinactive ribozymes had no effect on elimination of the hcrah/ mRNA signal (data not shown). RT-PCR using primers that amplified the &actin gene confirmed that similar quantities of RNA were used in RT-PCR amplification for the hcrah/ mRNA signal (data not shown). These results show that delivery of a triple-unit ribozyme using folic acid-polylysine reduces the levels of hcr-nhl RNA by 3 logs, whereas only a l-log reduction is achieved with liposomes. These results are consistent with the levels of ribozyme present in cells after transfection using these two reagents. mRNA and an abnormal p210'""""' tyrosine kinase.' This appears to be the transforming signal that leads to the development of CML.') There are no conventional therapies that have resulted in cures in CML, including chemotherapy. "P, and splenic irradiation.'." In S% to 15% of patients. m-interferon therapy may suppress the expression of the Ph-positive clone in CML.'""' However, the ability of interferon to cure CML has not been shown. Allogeneic BMT. using HLA-identical siblings, after myeloablative chemoradiotherapy is curative in up to 85% of carefully selected patients in chronic phase CML.Z"'3 In CML patients transplanted with BM grafts from an identical twin after high dose myeloablative therapy. the cure rate is 50%. This difference is because of a graft-versusleukemia (GVL) effect and is enhanced by the presence of chronic graft-versus-host disease. T-cell depletion of donor BM reduces both the GVL effect and the incidence of graftversus-host disease, as well as the cure rate." Collectively, these data show that high-dose therapy administered early in the course of CML is potentially curative in 50% of patients. The additional curative effects of allogeneic BMT are because of a GVL effect.
Less than 30% of CML patients will have a normal alloge- neic HLA-matched donor. Current use of matched unrelated donors has resulted in high mortality because of GVHD and infections..'' Thus, the development of an autologous BM transplant program using Ph-negative stem cells would provide an alternative for patients without other curative options. An autologous BMT would avoid GVHD and should be curative in up to 50% of patients, provided the BM is purged free of CML stem cells. Thus far, autologous BMT has not been successful in CML because Ph-positive stem cells are invariably reinfused into the patient.36 In an attempt to provide Ph-negative stem cells for autologous BMT, chemotherapy p~rging,'~ interferon purging,.'' long-term BM cultures,.'" and CD34 antigen-based stem cell selection4" result only in transient Ph-negative hematopoiesis.
Szcyzlik et all' reported the inhibition of proliferation of isolated blasts from CML patients after the addition of antisense oligonucleotides directed against the bcr-ab/ gene in vitro. More recently, we and other^").^".^' have reported the use of single-unit ribozyme molecules for cleavage of bcr-ab1 mRNA that, in turn, appeared to reduce or eliminate the synthesis of bcr-ab1 protein. Reduction in bcr-ab/ RNA with single-unit ribozymes appeared variable and, to a large extent, was dependent on ribozyme activity and intracellular levels. Therefore, it was a logical next step to develop ribozymes with increased catalytic activity. Analysis of the sequence of the bcr-ab1 gene adjacent to the fusion site showed 3 GUX sequences in close proximity. Therefore, we attempted to generate ribozymes that can bind to bcr-ab1 mRNA and cleave all the three sites that lie in close proximity to the junction point. Results presented in this report show that a triple-unit ribozyme has substantially increased catalytic potential when compared with single, double, or mixtures of individual ribozymes. Furthermore, the kinetics of cleavage show that the triple-unit ribozyme functions quickly. This may provide an additional advantage in the intracellular environment where nucleases would be present. Similar results have been described for a nonaribozyme targeting HIV-I env RNA."2 An important consequence of targeting normal sequences of the bcr and ab1 genes in the proximity of the fusion site is that normal mRNA may be affected by the ribozyme. Although we observe cleavage of normal bcr and ab1 mRNA, this appears to be less efficient in in vitro cell-free cleavage experiments than bcr-ab/ cleavage. This could be caused by extensive nonhomology of portions of the ribozyme to normal ab/ and hcr RNAs that, in turn, could reduce the affinity of the ribozyme to the substrate.
To develop a protocol for ribozyme-mediated treatment of human CML, both efficiency of delivery and ease of application need to be taken into consideration. To accomplish rapid and efficient delivery of ribozymes into myeloid cells, we used three different methods. The first method tried was the receptor-mediated uptake of naked oligonucleotides:? which proved to be extremely inefficient, possibly because of the delivery of the nucleotide molecules via the endosomal pathway, which exposes the ribozyme molecules to various nucleases of the cell. We next studied nontargeted uptake via cationic lipids and receptor-mediated uptake via the folate receptor. Both augmented ribozyme delivery to 32D cells, although folate-receptor-mediated uptake was more efficient. However, only folic acid-polylysinc-mcdiated delivery of the ribozymes seemed to affect bcr-ab1 mRNA levels significantly. Although we cannot rule out a quantitative effect because of improved delivery of ribozymes via folate receptor uptake, the intracellular compartment accessible to ribozymes may be more favorable by this technique.4 As reviewed by Gottschalk et a1,4" folate enters cells through several different receptor systems, including a glycosyl-phosphatidyl-anchored protein that is excluded from clathrin-coated pits and cycles in and out of cells by caveolae."" RNA transfected via liposomes may be quickly degraded:7 because this uptake is mediated via an endosomal Control - For personal use only. on November 16, 2017. by guest www.bloodjournal.org From pathway, which exposes the ribozymes to cellular nucleases. On the other hand, receptor-mediated uptake may protect the ribozymes from intracellular degradation caused by exposure to cellular nucleases. Folate-mediated uptake may suffer from a first-dose effect if receptors are downregulated after ligand binding. In such an event, the problem could be circumvented by targeting different receptors sequentially. Our results show that, although transfection efficiency decreases with serial transfections, ribozymes continue to be delivered into cells when transfections are separated over a 24-hour time period.
The ultimate measure of ribozyme effects on bcr-abl mRNA are decreasing the bcr-abl mRNA signal, reducing p2 10hcr~ah' protein levels, and reversing the transformed phenotype in living cells. Our results show a reduction in bcrab1 mRNA levels in transformed 32D cells when transfected with ribozymes delivered by folate receptor-mediated uptake. Unfortunately, multiple sequential transfections did not improve on the results obtained by a single transfection over 24 hours. It is possible that constitutive expression of ribozymes transfected by retroviruses in a similar model may show greater efficacy.
